Breast cancer, cytomegalovirus and Epstein-Barr virus: a nested case-control study.
BACKGROUND
We investigated whether elevation in serum cytomegalovirus (CMV) or Epstein-Barr virus (EBV) immunoglobulin G (IgG) antibody levels precedes the development of breast cancer.


METHODS
A nested case-control study was carried out within the Janus Serum Bank cohort. Two serum samples, one taken at least 4 years before diagnosis (sample 2) and an earlier sample (sample 1) from 399 women with invasive breast cancer and from 399 controls, matched for date of blood samples and age were tested for CMV and EBV IgG antibodies. Odds ratios (ORs) with 95% confidence intervals (CIs) for CMV and EBV seroconversion between the samples and unit changes in IgG optical density (OD) examined as a continuous variable were calculated using conditional logistic regression.


RESULTS
Eleven cases and three controls seroconverted for CMV IgG between the first and second blood samples, with an adjusted OR for CMV IgG seroconversion of 4.0 (95% CI=1.1-14.4). The risk of breast cancer, adjusted for parity, increased per unit difference in CMV OD between samples (OR=1.7, 95% CI=1.1-2.5). In an analysis restricted to parous cases and age-matched parous controls, the OR for CMV seroconversion for IgG between the two samples, adjusted for parity and age at first birth, was 9.7 (95% CI=1.2-77.3). The EBV seroconversion or change in EBV OD was not associated with risk of breast cancer.


CONCLUSIONS
Our hypothesis that elevation in serum CMV IgG antibody levels precedes the development of breast cancer in some women is supported by the results of this study. Changes in EBV IgG antibody are not associated with risk of breast cancer.
Cox
B
B
Department of Preventive and Social Medicine, Hugh Adam Cancer Epidemiology Unit, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. brian.cox@otago.ac.nz
Richardson
A
A
Graham
P
P
Gislefoss
R E
RE
Jellum
E
E
Rollag
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood / Q000150:complications / Q000453:epidemiology* / Q000821:virology; D002277:Carcinoma / Q000097:blood / Q000150:complications / Q000453:epidemiology* / Q000821:virology; D016022:Case-Control Studies; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology*; D020031:Epstein-Barr Virus Infections / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology*; D005260:Female; D004854:Herpesvirus 4, Human / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000097:blood; D008875:Middle Aged; D010298:Parity; D011247:Pregnancy; D012698:Serologic Tests; D055815:Young Adult
D000914:Antibodies, Viral; D007074:Immunoglobulin G
N Engl J Med. 1994 Jul 7;331(1):5-9
8202106
Clin Diagn Lab Immunol. 1995 Jan;2(1):25-9
7719908
Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):9-16
11205495
JAMA. 2005 May 25;293(20):2466
15914742
Med Hypotheses. 1997 Jun;48(6):491-7
9247892
Epidemiol Rev. 1993;15(1):220-31
8405206
J Intern Med. 2006 Mar;259(3):219-46
16476101
Br J Cancer. 2004 Jun 1;90(11):2149-52
15150559
Environ Health Perspect. 1995 Apr;103 Suppl 3:85-8
7635118
Rev Med Virol. 2004 May-Jun;14(3):169-77
15124233
Microsc Res Tech. 2005 Nov;68(3-4):197-208
16276516
Occup Med (Lond). 2005 Oct;55(7):564-7
16251375
Br J Cancer. 2003 Jul 7;89(1):113-9
12838311
Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):688-97
15159298
Arch Med Res. 2005 Sep-Oct;36(5):590-3
16099343
Sci Total Environ. 1993 Nov 1;139-140:527-35
8272856
Occup Med (Lond). 1999 Sep;49(7):427-37
10665144